검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | EC chemotherapy |
Overview Company | Jiangsu HengRui Medicine Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer Invasive |
Overview Indication | Breast Cancer Invasive |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | Targeting Autophagy in Alzheimer's Disease: Role of the AMPK/mTOR Pathway |
MoA Biomarker | biomarkers for lower cardiotoxicity induced by EC-D neoadjuvant chemotherapy in BC patients |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.. Neutropenia is the most severe hematologic toxicity of myelosuppressive chemotherapy. The objective of this study was to evaluate the safety and efficacy of efbemale… |
Clinical Primary efficacy | ORR 25% |
Clinical ORR | 25% |
Clinical Result source | ClinicalTrials.gov NCT01869192 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | EC chemotherapy |
Overview Company | Jiangsu HengRui Medicine Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer Invasive |
Overview Indication | Breast Cancer Invasive |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | Targeting Autophagy in Alzheimer's Disease: Role of the AMPK/mTOR Pathway |
MoA Biomarker | biomarkers for lower cardiotoxicity induced by EC-D neoadjuvant chemotherapy in BC patients |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.. Neutropenia is the most severe hematologic toxicity of myelosuppressive chemotherapy. The objective of this study was to evaluate the safety and efficacy of efbemale… |
Clinical Primary efficacy | ORR 25% |
Clinical ORR | 25% |
Clinical Result source | ClinicalTrials.gov NCT01869192 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교